VANC Pharmaceuticals Receives NPNs From Health Canada For 4 Products
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 11/19/14 -- VANC Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Natural Product Number (the "NPN") approvals for: FerroHEME (heme-iron supplement), PEDIA-SAFE drops (multivitamin dietary supplement for infant and children), SennaLax (natural laxative) and T36 Ointment (disinfectant and corticosteroid). The NPN approvals allow Vanc to manufacture, market and sell all 4 products immediately.
The Canadian market for these 4 products is estimated to be $90 million annually. Vanc plans to manufacture these products and start sales and marketing activities for them beginning in Q1-2015.
"In addition to our growing generic drug portfolio we recognize the importance of providing the market with novel and proprietary over the counter (the "OTC") products. The 4 products that have received NPNs represent a broad spectrum offering of high margin OTC products," said Arun Nayyar, CEO of Vanc. "Our market research and outreach within our target market validates the need and demand for each of these products. Early interest from customers has been positive."
Table 1.0 provides a summary description of each of the 4 products.
On behalf of:
Vanc Pharmaceuticals Inc.
Jamie Lewin, Director and CFO
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC''s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Vanc Pharmaceuticals Inc.
Jamie Lewin
Director and CFO
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.11.2014 - 08:00 Uhr
Sprache: Deutsch
News-ID 1319715
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 72 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"VANC Pharmaceuticals Receives NPNs From Health Canada For 4 Products
"
steht unter der journalistisch-redaktionellen Verantwortung von
Vanc Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
